United Therapeutics Corporation (NASDAQ:UTHR – Get Free Report) CEO Martine Rothblatt sold 9,500 shares of the business’s stock in a transaction on Wednesday, September 2nd. The stock was sold at an average price of $493.46, for a total value of $4,687,870.00. Following the completion of the transaction, the chief executive officer directly owned 324,443 shares in the company, valued at approximately $160,099,642.78. This represents a 2.84% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.
United Therapeutics Price Performance
Shares of NASDAQ:UTHR traded down $1.78 during midday trading on Thursday, reaching $490.24. The company’s stock had a trading volume of 469,574 shares, compared to its average volume of 494,247. United Therapeutics Corporation has a fifty-two week low of $375.61 and a fifty-two week high of $609.35. The company has a market capitalization of $21.03 billion, a P/E ratio of 17.54, a P/E/G ratio of 2.56 and a beta of 0.56. The business’s fifty day simple moving average is $528.12 and its 200-day simple moving average is $539.79.
United Therapeutics (NASDAQ:UTHR – Get Free Report) last issued its quarterly earnings results on Wednesday, August 5th. The biotechnology company reported $7.27 earnings per share (EPS) for the quarter, topping the consensus estimate of $6.86 by $0.41. United Therapeutics had a net margin of 41.56% and a return on equity of 20.18%. The business had revenue of $783.30 million for the quarter, compared to the consensus estimate of $804.65 million. During the same quarter in the prior year, the company earned $6.41 EPS. The firm’s quarterly revenue was down 1.9% on a year-over-year basis. On average, analysts forecast that United Therapeutics Corporation will post 26.33 earnings per share for the current fiscal year.
Institutional Investors Weigh In On United Therapeutics
Analyst Ratings Changes
Several analysts have recently commented on UTHR shares. Bank of America decreased their price target on shares of United Therapeutics from $620.00 to $613.00 and set a “neutral” rating on the stock in a research note on Friday, July 10th. Royal Bank Of Canada dropped their price objective on shares of United Therapeutics from $704.00 to $677.00 and set an “outperform” rating for the company in a research report on Thursday, August 6th. Weiss Ratings downgraded United Therapeutics from a “buy (b)” rating to a “buy (b-)” rating in a report on Thursday, August 27th. TD Cowen reiterated a “buy” rating on shares of United Therapeutics in a research report on Thursday, May 21st. Finally, Wells Fargo & Company raised United Therapeutics from an “equal weight” rating to an “overweight” rating and lifted their target price for the company from $575.00 to $735.00 in a research note on Thursday, May 7th. Eleven investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $646.00.
View Our Latest Stock Report on UTHR
About United Therapeutics
United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.
Featured Articles
- Five stocks we like better than United Therapeutics
- The Path to $230 Billion: Broadcom Outlines the Next Phase of Its AI Growth Story
- NVIDIA’s Hugging Face Deal Raises a Bigger Question About Its AI Moat Now
- Dropping the Dough: Yum! Brands Strategically Trims the Fat
- These 3 Stock Charts Just Flashed the Dreaded Death Cross Pattern
Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
